Short Interest in Lonza Group Ag (OTCMKTS:LZAGY) Increases By 34.6%

Lonza Group Ag (OTCMKTS:LZAGY) saw a large growth in short interest during the month of March. As of March 31st, there was short interest totaling 5,253 shares, a growth of 34.6% from the March 15th total of 3,903 shares. Based on an average trading volume of 171,137 shares, the short-interest ratio is presently 0.0 days. Currently, 0.0% of the company’s stock are sold short.

Lonza Group Stock Up 0.7%

LZAGY stock traded up $0.48 during trading on Wednesday, reaching $68.12. The stock had a trading volume of 19,892 shares, compared to its average volume of 96,350. The company’s 50 day moving average is $64.99 and its two-hundred day moving average is $67.07. The company has a current ratio of 2.24, a quick ratio of 1.77 and a debt-to-equity ratio of 0.42. Lonza Group has a one year low of $58.53 and a one year high of $73.85.

Wall Street Analyst Weigh In

LZAGY has been the topic of a number of analyst reports. Royal Bank Of Canada upgraded shares of Lonza Group from a “hold” rating to a “moderate buy” rating in a report on Wednesday, February 11th. Zacks Research raised shares of Lonza Group from a “strong sell” rating to a “hold” rating in a research report on Wednesday, April 8th. One investment analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy”.

Lonza Group Company Profile

Lonza Group is a Swiss multinational life sciences company that provides products and services to the pharmaceutical, biotech and specialty ingredients markets. Headquartered in Switzerland, the company operates globally with manufacturing and research facilities across Europe, North America and Asia, serving customers involved in drug discovery, development and commercial production. Lonza’s client base ranges from large pharmaceutical firms to emerging biotech companies and manufacturers of consumer health and specialty chemical products.

The company’s core activities center on contract development and manufacturing (CDMO) for small molecules and biologics, including process development, clinical and commercial-scale manufacturing, and fill–finish services.